Part One: Performance Analysis

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company that has a focus on developing novel therapeutics that target specific viral diseases. The company has directed its efforts towards hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. As of March 31, 2023, Arbutus had cash and cash equivalents and available-for-sale securities of $222.9 million. The company also believes it has sufficient cash resources to fund its operations through the first quarter of 2025.

During the quarter, Arbutus made significant progress towards its goal of discovering and developing a curative combination regimen for chronic hepatitis B infection. In March 2023, the company initiated a Phase 1 clinical trial with AB-161, an oral RNA destabilizer, and continues to evaluate AB-729, an RNAi therapeutic, in multiple Phase 2 clinical trials. The company believes that AB-729 is the only RNAi therapeutic with evidence of immune reawakening. Arbutus is also exploring oncology applications for its internal PD-L1 portfolio.

The company has a diversified pipeline, with programs directed towards different viral diseases. This approach helps to minimize the risk associated with a narrow focus. Arbutus continues to make progress in its efforts to develop treatments for viral diseases that currently have few effective treatments. However, the company operates in a highly competitive industry, and its success will depend on its ability to compete effectively against other biopharmaceutical companies that are also working to develop treatments for viral diseases.

Part Two: Forward Looking Analysis

Arbutus Biopharma Corporation has positioned itself well in the fight against viral diseases, particularly in hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. The company has a diversified pipeline with programs directed toward different viral diseases, which helps to minimize the risk associated with a narrow focus. The company has advanced its product candidates in Phase 2 clinical trials and has initiated a Phase 1 clinical trial for AB-161. Arbutus expects to announce data from its ongoing clinical trials in the future, which could provide insight into the potential of its product candidates.

Arbutus has a strong cash position that the company believes is sufficient to fund its operations through the first quarter of 2025. The company plans to obtain necessary regulatory approvals and adequate financing through a combination of financing activities and operations. As such, Arbutus' financial position remains positive.

In conclusion, Arbutus Biopharma Corporation has made significant progress towards its goal of discovering and developing a curative combination regimen for chronic hepatitis B infection. The company has promising product candidates in its pipeline and a strong cash position to fuel its operations. However, Arbutus operates in a highly competitive industry, and its success will depend on its ability to compete effectively against other biopharmaceutical companies. As such, investors should monitor Arbutus closely and be aware of the competitive landscape in the viral disease treatment space.

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Arbutus Biopharma Corp

Arbutus Biopharma: Strong Pipeline & Cash Position for Viral Disease Treatments

Arbutus Biopharma Corporation reported its financial results for the first quarter of 2023, and provided an update on its clinical programs. The clinical-stage biopharmaceutical company is leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, including Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. Arbutus reported data from its lead HBV-focused RNAi therapeutic, AB-729, showing low levels of HBsAg and HBV DNA in most patients persisting for at least a year and a half after their last dose of AB-729. In addition, the company dosed the first healthy subject in its Phase 1 clinical trial with AB-161, its oral RNA destabilizer, for which it expects data in the second half of this year. Arbutus also continues to advance its coronavirus programs.

The company's financial position is solid, with cash and cash equivalents of $178.3 million as of December 31, 2022, which is sufficient to fund its operations into the first quarter of 2025. During the first quarter of 2023, Arbutus recorded a net loss of $27.1 million, compared to a net loss of $6.6 million in the same period of the previous year. The increase in net loss was primarily due to the discontinuation of a Phase 1b clinical trial, which was partially offset by an increase in expenses for its coronavirus program and other early-stage development programs. The company had approximately 165.1 million common shares issued and outstanding, as well as approximately 19.7 million stock options and unvested restricted stock units outstanding as of March 31, 2023.

Overall, Arbutus Biopharma Corporation's update on its clinical programs and solid financial position should be reassuring to investors. However, investors should remain cautious, as drug development is a complex and risky process that involves many uncertainties and contingent factors. Therefore, investors should do their own research and consult with financial advisors before making any investment decisions.

Form 8-K - Current report - Item 2.02 Item 8.01 Item 9.01

$ABUS reports Positive Clinical Data for HBV-focused Therapeutic and Robust Financial Position for Q1 2023

Form 8-K - Current report - Item 8.01 Item 9.01

Arbutus Biopharma: Strong Pipeline & Cash Position for Viral Disease Treatments

Arbutus Biopharma: Strong Pipeline & Cash Position for Viral Disease Treatments

$ABUS reports Positive Clinical Data for HBV-focused Therapeutic and Robust Financial Position for Q1 2023

$ABUS reports Positive Clinical Data for HBV-focused Therapeutic and Robust Financial Position for Q1 2023

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing

Announcement: ABUS 8-K Special Filing